Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension

Journal of Hypertension

Volumn 31, Issue 4, 2013, Pages 820-829

  Gilbert, Kimberly ^a   Nian, Hui ^b   Yu, Chang ^b   Luther, James M ^a   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

blood pressure; fenofibrate; hypertension; peroxisome proliferator activated receptor a; salt

Indexed keywords

EPOXYICOSATRIENOIC ACID; FENOFIBRATE; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; FEMALE; HEART RATE; HIGH SALT DIET; HUMAN; HYPERTENSION; HYPOTHESIS; KIDNEY ARTERY VASOCONSTRICTION; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALT INTAKE; SALT RESISTANT HYPERTENSION; SALT RESISTANT HYPETENSION; SALT SENSITIVE HYPERTENSION; SALT SENSITIVE HYPETENSION; SODIUM EXCRETION; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; URINALYSIS; VASOCONSTRICTION; WEIGHT GAIN;

EID: 84875220954     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835e8227     Document Type: Article

References (31)

1. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care 2011; 34:216-219.
2. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-1861.
3. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370:1687-1697.
4. Nissen SE, Nicholls SJ, Wolski K, Howey DC, McErlean E, Wang MD, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA 2007; 297:1362-1373.
5. Jonkers IJ, de Man FH, van der LA, Frolich M, Gevers Leuven JA, Kamper AM, et al. Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. J Hypertens 2001; 19:749-755.
6. Chew GT, Watts GF, Davis TM, Stuckey BG, Beilin LJ, Thompson PL, et al. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 2008; 31:1502-1509.
7. Subramanian S, DeRosa MA, Bernal-Mizrachi C, Laffely N, Cade WT, Yarasheski KE, et al. PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans. Am J Physiol Endocrinol Metab 2006; 291:E1365-E1371.
8. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357:905-910.
9. Roman RJ, Ma YH, Frohlich B, Markham B. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension 1993; 21:985-988.
10. Zhou Y, Luo P, Chang HH, Huang H, Yang T, Dong Z, et al. Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension. Kidney Int 2008; 74:1040-1048.
11. Lee DL, Wilson JL, Duan R, Hudson T, El-Marakby A. Peroxisome proliferator-activated receptor-alpha activation decreases mean arterial pressure, plasma interleukin-6, and COX-2 While increasing renal CYP4A expression in an acute model of DOCA-salt hypertension. PPAR Res 2011; 2011:502631.
12. Nakagawa K, Holla VR, Wei Y, Wang WH, Gatica A, Wei S, et al. Saltsensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J Clin Invest 2006; 116:1696- 1702.
13. Banks T, Oyekan A. Peroxisome proliferator-activated receptor alpha activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat. J Hypertens 2008; 26:468-477.
14. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 2004; 36:295- 304.
15. Muller DN, Theuer J, Shagdarsuren E, Kaergel E, Honeck H, Park JK, et al. A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin IIinduced renal injury. Am J Pathol 2004; 164:521-532.
16. Zhao X, Imig JD. Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 2003; 4:73-84.
17. Sankaralingam S, Desai KM, Glaeser H, Kim RB, Wilson TW. Inability to upregulate cytochrome P450 4A and 2C causes salt sensitivity in young Sprague-Dawley rats. Am J Hypertens 2006; 19:1174-1180.
18. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 1998; 31:225-231.
19. Obih P, Oyekan AO. Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPARalpha null mice. Blood Press 2008; 17:55-63.
20. Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, Hollenberg NK. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest 1983; 72:2115- 2124.
21. Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension 2012; 59:893-898.
22. Holmes C, Eisenhofer G, Goldstein DS. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using highperformance liquid chromatography with electrochemical detection. J Chromatogr 1994; 653:131-138.
23. Karara A, Wei S, Spady D, Swift L, Capdevila JH, Falck Jr. Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma. Biochem Biophys Res Commun 1992; 182:1320-1325.
24. Capdevila JH, Wei S, Kumar A, Kobayashi J, Snapper JR, Zeldin DC, et al. Resolution of dihydroxyeicosanoates and of dihydroxyeicosatrienoates by chiral phase chromatography. Anal Biochem 1992; 207: 236-240.
25. Falck JR, Anjaiah S, Tuniki VR, Gopal VR, Capdevila JH. Convenient syntheses of [20,20,20-H(3)]-arachidonic acid and [20,20-H(2)]-20- hydroxyeicosatetraenoic acid. J Labelled Comp Radiopharm 2006; 49:245-252.
26. Jones B, Kenward MG. Design and analysis of crossover trials. Boca Raton, FL: CRC Press LLC; 2003.
27. Melenovsky V, Wichterle D, Simek J, Malik J, Haas T, Ceska R, et al. Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia. Am J Cardiol 2003; 92:337-341.
28. Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, et al. Angiotensin II upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A 2007; 104:9018-9023.
29. Pinot F, Grant DF, Spearow JL, Parker AG, Hammock BD. Differential regulation of soluble epoxide hydrolase by clofibrate and sexual hormones in the liver and kidneys of mice. Biochem Pharmacol 1995; 50:501-508.
30. Pozzi A, Ibanez MR, Gatica AE, Yang S, Wei S, Mei S, et al. Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis. J Biol Chem 2007; 282:17685-17695.
31. Laffer CL, Laniado-Schwartzman M, Wang MH, Nasjletti A, Elijovich F. HETE and furosemide-induced natriuresis in salt-sensitive essential hypertension. Hypertension 2003; 41:703-708.